Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None202320222021202020192018201720162015 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting 04/04/2017 Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs 01/03/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting 12/05/2016 Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting 11/03/2016 Poseida Therapeutics Establishes Scientific Advisory Board 09/08/2016 Poseida Therapeutics Expands Executive Leadership Team 08/18/2016 Poseida Therapeutics Announces Series A Financing 12/16/2015 Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies 08/11/2015 Poseida Therapeutics, Inc., Expands Board of Directors 08/05/2015 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Next page next › Last page last » Displaying 101 - 110 of 112
Year None202320222021202020192018201720162015 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting 04/04/2017 Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs 01/03/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting 12/05/2016 Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting 11/03/2016 Poseida Therapeutics Establishes Scientific Advisory Board 09/08/2016 Poseida Therapeutics Expands Executive Leadership Team 08/18/2016 Poseida Therapeutics Announces Series A Financing 12/16/2015 Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies 08/11/2015 Poseida Therapeutics, Inc., Expands Board of Directors 08/05/2015 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Next page next › Last page last » Displaying 101 - 110 of 112
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting 04/04/2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting 12/05/2016
Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting 11/03/2016
Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies 08/11/2015